Seeking Alpha
Long/short equity, insider ownership
Profile| Send Message|
( followers)  

Since my December 13, 2012, article titled "5 Stocks With Recent Intensive Insider Buying", the stocks that I featured have performed as follows:

Company Price 12/12 Price 3/18 Change
Healthcare Trust of America (NYSE:HTA) $9.88 $11.95 +21.0%
Western Asset Mortgage Capital Corporation (NYSE:WMC) $20.66 $22.87 +10.7%
Glu Mobile (NASDAQ:GLUU) $2.46 $3.61 +46.7%
NTELOS Holdings (NASDAQ:NTLS) $13.36 $12.96 -3.0%
Metabolix (NASDAQ:MBLX) $1.69 $2.40 +42.0%

In this article, I will feature three additional stocks that have seen intensive insider buying during the last 30 days. Intensive insider buying can be defined by the following three criteria:

  1. The stock is purchased by three or more insiders within one month.
  2. The stock is sold by no insiders in the month of intensive purchasing.
  3. At least two purchasers increase their holdings by more than 10%.

1. Navidea Biopharmaceuticals (NYSEMKT:NAVB), a biopharmaceutical company, engages in the development and commercialization of precision diagnostics and radiopharmaceutical agents.


(Click to enlarge)

Insider buying by insider (last 30 days)

  • Gordon Troup purchased 7,000 shares on March 15 and currently holds 126,250 shares or 0.1% of the company. Gordon Troup has served as a director of Navidea since July 2008.
  • Mark Pykett purchased 1,850 shares on March 15 and currently holds 355,914 shares or 0.3% of the company. Dr. Mark Pykett has been President and Chief Executive Officer of Navidea since April 2011.
  • Brendan Ford purchased 5,000 shares on March 15 and currently holds 119,250 shares or 0.1% of the company. Brendan Ford has served as a director of Navidea since July 2010.
  • William Regan purchased 5,000 shares on March 15 and currently holds 5,000 shares or less than 0.1% of the company. William Regan is Senior Vice President, Global Regulatory Strategy.
  • Thomas Tulip purchased 17,500 shares on March 15 and currently holds 45,000 shares or less than 0.1% of the company. Dr. Thomas Tulip has served as Executive Vice President and Chief Business Officer at Navidea since June 2011.

Insider buying by calendar month

Here is a table of Navidea's insider trading activity by calendar month.

Month Insider buying / shares Insider selling / shares
March 2013 36,350 0
February 2013 0 0
January 2013 0 0
December 2012 0 0
November 2012 0 0
October 2012 37,030 0
September 2012 34,000 708,382
August 2012 0 0
July 2012 0 0
June 2012 0 0
May 2012 0 0
April 2012 0 0
March 2012 0 0
February 2012 0 0

The month of March 2013 has seen the most insider buying since October 2012.

Financials

The company reported the full year 2012 financial results on March 6 with the following highlights:

Revenue $79,000
Net loss $29.2 million
Cash $9.1 million
Debt $9.7 million

On July 26, 2012, Navidea implemented a $50 million credit facility with Platinum-Montaur Life Sciences LLC to provide flexible financial resources to fund short- and long-term development and growth plans. To date the company has drawn a total of $4 million under the credit facility. Montaur also exercised certain warrants in December 2012 and March 2013, providing $1.9 million and $1.4 million in proceeds, respectively.

Outlook

The company believes that its cash flow and available financial resources are sufficient to support the ongoing advances in its pipeline programs and operating needs for the foreseeable future.

Lymphoseek Competition

Surgeons who practice the lymphatic mapping procedure for which Lymphoseek is intended currently use other radiopharmaceuticals such as a sulfur colloid compound in the U.S., and other colloidal compounds in other markets. In addition, many surgeons use vital blue dyes to assist in the visual identification of the draining lymphatic tissue around a primary tumor. In the U.S., sulfur colloid is manufactured by Pharmalucence. Sulfur colloid had been used "off-label" in the U.S. for ILM until July 2011, when it was approved by the FDA for use in lymphatic mapping in breast cancer patients based on a statistical meta-analysis of published literature that compared the use of sulfur colloid with that of the vital blue dyes. The product label for sulfur colloid was expanded to cover lymphatic mapping in melanoma in August 2012, again on the basis of a meta-analysis of published literature. In the EU and certain Pacific Rim markets, there are other colloidal-based compounds with various levels of approved labeling for use in lymphatic mapping, although a number of countries still employ the use of products used "off-label".

My analysis

The stock has a $6.25 price target from the Point and Figure chart. There have been five different insiders buying the shares and there have not been any insiders selling the shares during the last 30 days. There are two analyst buy ratings, two neutral ratings and one sell rating with an average target price of $3.40. On March 13, Navidea announced U.S. Food and Drug Administration approval of Lymphoseek. The company expects to make a formal launch of Lymphoseek in the next quarter and therefore generate revenue in Q2. The EU approval decision for Lymphoseek is expected in Q4/2013 or Q1/2014. I have a long position in the stock currently.

2. Park City Group (NASDAQ:PCYG) operates as a Software-as-a-Service [SaaS] provider that brings unique visibility to the consumer goods supply chain, delivering actionable information.


(Click to enlarge)

Insider buying by insider (last 30 days)

  • Robert Hermanns purchased 55,556 shares on March 14 pursuant to a private placement. Robert Hermanns currently holds 113,019 shares or 0.9% of the company. Robert Hermanns serves as a director of the company.
  • Austin Noll purchased 16,667 shares on March 14 pursuant to a private placement. Austin Noll currently holds 17,500 shares or 0.1% of the company. Austin Noll serves as a director of the company.
  • Robert Allen purchased 138,889 shares on March 14 pursuant to a private placement. Robert Allen currently holds 394,121 shares or 3.2% of the company. Robert Allen serves as a director of the company.
  • James Gillis purchased 30,000 shares on March 14 pursuant to a private placement. James Gillis currently holds 137,197 shares or 1.1% of the company. James Gillis serves as a director of the company.
  • Ronald Hodge purchased 194,445 shares on March 14-15 pursuant to a private placement. Ronald Hodge currently holds 194,445 shares or 1.6% of the company. Ronald Hodge serves as a director of the company.
  • Richard Juliano purchased 5,556 shares on March 14 pursuant to a private placement. Richard Juliano currently holds 6,389 shares or less than 0.1% of the company. Richard Juliano serves as a director of the company.
  • William Kies purchased 8,334 shares on March 14 pursuant to a private placement. William Kies currently holds 13,766 shares or 0.1% of the company. William Kies serves as a director of the company.
  • Randall Fields purchased 20,834 shares on March 14 pursuant to a private placement. Randall Fields currently holds 3,966,292 shares or 31.8% of the company. Randall Fields serves as a director of the company.

Insider buying by calendar month

Here is a table of Park City Group's insider trading activity by calendar month.

Month Insider buying / shares Insider selling / shares
March 2013 470,281 0
February 2013 0 0
January 2013 0 0
December 2012 0 0
November 2012 0 15,800
October 2012 0 0
September 2012 0 0
August 2012 0 0
July 2012 0 0
June 2012 0 0
May 2012 0 0
April 2012 0 0
March 2012 0 0
February 2012 0 0

The month of March 2013 has seen all of the insider buying.

Financials

The company reported the second-quarter fiscal 2013, which ended December 31, 2012, financial results on February 14 with the following highlights:

Revenue $2.7 million
Net loss $0.4 million
Cash $1.1 million
Debt $2.4 million

Competition

Here is a table comparing Park City Group against the Business Software and Services sector.

Company PCYG Industry Average (Business Software & Services)
Market Cap: 44.43M 61.66M
Employees: 48 865.00
Qtrly Rev Growth (yoy): 0.04 0.13
Revenue: 10.32M 64.80M
Gross Margin: 0.56 0.38
EBITDA: 350.05K 5.10M
Operating Margin: -0.04 0.09
Net Income: -1.18M N/A
EPS: -0.10 0.22
P/E: N/A 20.81
PEG (5 yr expected): N/A 1.26
P/S: 4.36 1.34

Park City Group is trading above the industry average P/S ratio.

My analysis

There have been eight different insiders buying the shares and there have not been any insiders selling the shares during the last 30 days. The management and board owns 46% of the company and the institutions own 13% of the company. I have a cautiously bullish bias for the stock currently based on the high insider ownership level and the intensive insider buying.

3. JMP Group (NYSE:JMP) provides investment banking and asset management services in the United States.


(Click to enlarge)

Insider buying by insider (last 30 days)

  • Kenneth Karmin purchased 16,798 shares on March 13-15 and currently controls 93,861 shares or 0.4% of the company. Kenneth Karmin serves as a member of the board of directors of JMP Group.
  • Craig Johnson purchased 25,000 shares on March 12 and currently controls 1,110,557 shares or 4.9% of the company. Craig Johnson is the vice chairman and a member of the executive committee.
  • Jonathan Orszag purchased 20,000 shares on March 12 and currently controls 28,982 shares or 0.1% of the company. Jonathan Orszag serves as a member of the board of directors of JMP Group.

Insider buying by calendar month

Here is a table of JMP Group's insider trading activity by calendar month.

Month Insider buying / shares Insider selling / shares
March 2013 61,798 0
February 2013 0 0
January 2013 0 0
December 2012 0 0
November 2012 0 0
October 2012 0 0
September 2012 0 0
August 2012 0 0
July 2012 0 0
June 2012 0 0
May 2012 0 0
April 2012 0 0
March 2012 0 0
February 2012 0 0

The month of March 2013 has seen all of the insider buying.

Financials

The company reported the full year 2012 financial results on February 13 with the following highlights:

Revenue $101.9 million
Net income $2.8 million
Tangible book value $5.62 per share

Competition

Here is a table comparing JMP Group against the Investment Brokerage sector.

Company JMP Industry Average (Investment Brokerage - National)
Market Cap: 148.15M 240.45M
Employees: 224 571.00
Qtrly Rev Growth (yoy): 0.31 0.12
Revenue: 100.92M 223.46M
Gross Margin: 0.93 0.84
EBITDA: N/A 26.98K
Operating Margin: 0.09 0.13
Net Income: 2.76M N/A
EPS: 0.12 0.07
P/E: 54.58 14.80
PEG (5 yr expected): 0.69 1.19
P/S: 1.47 2.56

JMP Group is trading below the industry average P/S ratio, which could explain some of the insider buying.

My analysis

There have been three different insiders buying the shares and there have not been any insiders selling the shares during the last 30 days. The stock is trading at a P/E ratio of 54.58 and a forward P/E ratio of 8.73. The company has a tangible book value of $5.62 per share and the stock has a dividend yield of 2.14%. I would expect the tangible book value to act like a support for the stock.

Source: 1 Pharmaceutical, 1 Technology And 1 Financial Stock With Recent Intensive Insider Buying